F. . Donskov, N. . Viggo Jensen, and T. Smidt-Hansen, “A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1”, AO, vol. 57, no. 5, pp. 589–594, May 2018.